Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
Intellia Therapeutics' NTLA-5001 is positioned within the competitive landscape of CAR-T and TCR therapies for Acute Myeloid Leukemia (AML). The termination of this trial indicates a strategic pivot towards an allogeneic version of the therapy, which may enhance scalability and address manufacturing challenges associated with autologous therapies. The AML market is characterized by a growing demand for innovative treatments, particularly in relapsed/refractory cases, suggesting potential for significant market capture if the allogeneic version demonstrates safety and efficacy. Stakeholders should monitor developments closely as the allogeneic approach may offer a competitive edge over existing therapies.
Indication: Acute Myeloid Leukemia
Modality: gene therapy
Target: WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9
Sponsor: Intellia Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9
Target normalized: WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9